Information from Industry - CME Supplement

The Next Generation of Oral Contraception: Advances in Estrogens

Publish date: June 1, 2021
This activity is supported by an independent educational grant from Mayne Pharma.

 

Free CME Credit

This article traces the evolution of estrogen in contraception, with a special focus on the concept of native estrogen with specific actions in tissues, or NEST. Research surrounding estetrols (E4), receptor binding, and target interactions demonstrate that E4 has high selectivity for the estrogen receptors. Clinical trial data are presented that support the view that E4 — a high NEST activity estrogen — is a safe and effective estrogen for use in combined oral contraceptives. This premise was borne out with the approval of an estetrol/drosperinone combined oral contraceptive by the US Food and Drug Administration in April 2021.

Click here to read more


CME CREDITS: .25 CREDIT
To receive CME credit, please read the articles and go to www.omniaeducation.com/estrogen to access the posttest and evaluation.

Authors:

Patricia Geraghty, MSN, FNP-BC, WHNP
Hugh S. Taylor, MD

Next Article:

Managing deep infiltrating endometriosis